Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of $1.51, $2.43 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $41.37 million versus the consensus estimate of $44.89 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.